Pharmacogenomics Opportunities in Nuclear Receptor Targeted Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|2|3|243-256

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.2, Iss.3, 2002-01, pp. : 243-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Somatostatin Receptor-Targeted Anti-Cancer Therapy

By  

Current Drug Delivery, Vol. 8, Iss. 1, 2011-01 ,pp. : 2-10

Bentham Science Publishers

Access to resources Recommend Favorite

Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals

By  

Current Pharmaceutical Design, Vol. 14, Iss. 28, 2008-10 ,pp. : 3033-3047

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy

By  

Current Drug Delivery, Vol. 8, Iss. 1, 2011-01 ,pp. : 70-78

Bentham Science Publishers

Access to resources Recommend Favorite

The impact of pharmacogenomics on gastrointestinal cancer therapy

By Seufferlein Thomas   Boehm Bernhard O  

Pharmacogenomics, Vol. 3, Iss. 5, 2002-09 ,pp. : 625-633

Future Medicine

Access to resources Recommend Favorite

Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy

By  

Current Cancer Drug Targets, Vol. 4, Iss. 8, 2004-01 ,pp. : 673-687

Bentham Science Publishers

Access to resources Recommend Favorite